Thai study of opportunistic infx in Pediatric SLE - 177 pSLE, & 38 developed OI (3.4/100PY). Most common OIs: Candida (27%), Aspergillus (13.5%), CMV (13.5%) - lung & skin mostly. Risk factors: Pulse steroids, Dz activity (SLEDAI-2K ≥11) https://t.co/0zjDOnDCEh https://t.co/H7JZ56ItDY

Should You Use Low Dose Naltrexone? A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/lmjJoGlFAZ

RHEUM SURVEY>> How do you assess cutaneous lupus activity or treatment responses? Click here>> https://t.co/1HWC4DV55h https://t.co/X8MUqjxqys

Congratulations to John J. Cush, MD, of @RheumNow, recipient of the ACR Distinguished Clinician Scholar Award. The award recognizes his outstanding contributions to clinical medicine, scholarship, and education in rheumatology. #ACR26 https://t.co/9wWLjQNnxH

Lancet: A Public Health Policy Call Out for Osteoarthritis In honor of World Arthritis Day (Oct. 12th), The Lancet has published a public Health Policy report is to "outline a globally relevant roadmap to address the osteoarthritis identity problem, focusing on health policy https://t.co/XTRDJnOEGn

Placebo beats probiotics in PsA. And nearly 90% of well-controlled RA patients may be able to cut their targeted therapy dose in half. Dr. Jack Cush breaks down the findings worth a closer look in this week's RheumNow podcast, Troubles with ‘Gut Feelings’. Probiotics in PsA: https://t.co/Aqy4HxGHbU

Yale researchers propose repurposing the epilepsy drug, lacosamide, to treat osteoarthritis. In animal models, delivered as a hydrogel conjugate IA, improved cartilage repair, slowed deterioration, & reduced pain. Chosen as it blocks Sodium channels, esp Nav1.7 involved in pain https://t.co/ERJ2xPEyzl

Market info: Ankylosing Spondylitis market size in USA estimated at $3.3 billion USD in 2020 & is expected to increase 8.36% annually from 2019–2032. US prevalence of AS in 2020 was 1,300,971 cases https://t.co/EAginmKFF9 https://t.co/2Ye4Gk1awT

Italian GISEA (early RA) registry = 1304 pts Rx w/ JAK inhibitors. Retention rates at 6, 12, & 24 mos = 81%, 75%, & 61%. Low retention w/ baseline GC, high Dz activity, & pain. https://t.co/kKZmTHmEUb https://t.co/JlUUrFIU4G

Single center study of Probiotics in #PsA showed no benefit. 66 moderately active PsA pts (PASDAS>3.2) on stable Tx: Rx probiotic vs PBO x 12 wks. 56 pts analyzed, PASDAS <3 responders: 43% probiotic vs 65% PBO (P 0.167), w/ no change in gut permeability markers or stool https://t.co/0JUZ8SrRuw

92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/w5Gc3ntej0

"Perfection is not attainable, but if we chase perfection we can catch excellence." - Vince Lombardi https://t.co/KgQGp6mKlH

Symptomatic hand OA (HOA) increased signif in past decade in the Netherlands (esp women & older adults). PCP EHR study of 1.8 million Dutch patients ≥30 yrs. Betw 2013 & 2023, prevalence incr 65% (5.7 to 9.4%); incidence rose 20% (7.1 to 8.5/1000PY) https://t.co/HyqdwJ70y4 https://t.co/7fBngLO5w0

Univ Toronto lupus clinic study of 165 #SLE pts w/ Bx-proven LN (age 35.3 yrs; Dz dur 6.2 years). Half on antimalarial Rx. Being on HCQ did not alter Renal Bx outcomes (prolif GN, NIH AI, NIH CI, IFTA score. (But is known to improve renal outcomes) https://t.co/oQ0CgK7rXm https://t.co/PZX31wOPmL

Can DMARD Doses Be Safely Reduced for RA Patients? Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean https://t.co/MyjZdRaGb4